Begin typing your search above and press return to search.
Volume: 6 Issue: 4 November 2008 - Supplement - 1



Renal transplantation compared with dialysis can improve the life of patients with end stage renal disease. One of the contraindications of kidney transplantation is development of harmful antibodies in hemodialysis patients who are a candidate for kidney transplantation. These antibodies reduce the survival of grafted kidney and increase the risk of acute rejection. Panel Reactive Antibody (PRA) test is used for detecting these antibodies. Increase in panel reactive antibody titer is related to risk of hyper acute, acute and chronic graft rejection. Among kidney transplant candidates who are in waiting list for transplantation ,14 % have PRA above 80% and 15.9% have PRA between 10 and 79%.In some of the studies. Statins have been considered as useful agents for reducing the PRA. The current study, investigates the effect of Atorvastatin on PRA. In an experimental and interventional study 13 patients with end-stage renal disease who were candidates for kidney transplantation, received atorvastatin for 6 months. PRA for each patient was checked before treatment and then every 2 months after treatment for 3 times. Cholesterol, triglyceride and liver enzymes were checked before and after treatment. Data on Weight, height, past history of transfusion and kidney transplantation, cause of kidney disease and duration of dialysis were gathered via questionnaires. Mean of PRA was 61.93 ± 17.85 before treatment with atorvastatin and 51.15 ± 18.94, 43.75 ± 14.47 and 41.53 ± 22.94 at, 2, 4, and 6 months after treatment. Mean of total cholesterol before treatment was 147.69 ± 28.49 and after treatment 126.76± 22.24. Mean of LDL cholesterol was 86.44±25.76 before treatment and 70.23 ± 14.11 after treatment. These results showed significant reduction in PRA after treatment with atorvastatin and 2 months later. (P = 0.002, P = 0.001). Mean of total cholesterol and LDL showed significant reduction after treatment. (P = 0.005, P = 0.004) In conclusion, Atorvastatin significantly reduces PRA in kidney transplantation candidates as an effective, inexpensive and well-tolerated medication.

Volume : 6
Issue : 4
Pages : 90

PDF VIEW [1191] KB.

Isfahan kidney research center, Noor Hospital, Isfahan University of Medical Sciences, Isfahan, Iran